Status:
RECRUITING
Innovative Biomarkers of Cardiovascular Complications Associated With Second-generation Bruton Tyrosine Kinase Inhibitor Treatments: a Single-center Cohort Study
Lead Sponsor:
Centre Hospitalier Universitaire Dijon
Conditions:
Treatment With Second-generation Bruton's Tyrosine Kinase Inhibitors (Acalabrutinib, Zanubrutinib)
Eligibility:
All Genders
18+ years
Brief Summary
Second-generation Bruton's tyrosine kinase inhibitors (BTKIs) (zanubrutinib, acalabrutinib) are recently discovered oral targeted therapies used to treat hematological disorders such as chronic lympho...
Eligibility Criteria
Inclusion
- Patients eligible for treatment with second-generation Bruton's tyrosine kinase inhibitors in hematology (acalabrutinib, zanubrutinib)
- Patients aged 18 years and older
- Patients who have given their free and informed written consent to participate in this study after receiving information (or the patient's representative if the patient is unable to express consent themselves).
- Patients with a life expectancy estimated by the hematologist in charge of the patient to be greater than one year
Exclusion
- Persons not affiliated with or not covered by a social security system
- Patients subject to legal protection measures (guardianship, trusteeship)
- Patients subject to judicial protection measures
- Pregnant women, women in labor, or breastfeeding women
- Prior treatment with Bruton's tyrosine kinase inhibitors (ibrutinib, acalabrutinib, zanubrutinib)
- Follow-up planned at another center
- History of atrial fibrillation
- Uncontrolled hypertension
Key Trial Info
Start Date :
November 28 2025
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
November 1 2028
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT07174141
Start Date
November 28 2025
End Date
November 1 2028
Last Update
December 4 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
CHU Dijon Bourgogne
Dijon, France